Nova Zing Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 31-07-2024
- Paid Up Capital ₹ 1.19 M
as on 31-07-2024
- Company Age 29 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.90 Cr
as on 31-07-2024
- Satisfied Charges ₹ 1.10 Cr
as on 31-07-2024
- Revenue -2.90%
(FY 2023)
- Profit 1471.38%
(FY 2023)
- Ebitda 56.00%
(FY 2023)
- Net Worth 4.95%
(FY 2023)
- Total Assets 43.66%
(FY 2023)
About Nova Zing Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.19 M.
The company currently has active open charges totaling ₹7.90 Cr. The company has closed loans amounting to ₹1.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nitin Tamrakar and Kiran Tamrakar serve as directors at the Company.
- CIN/LLPIN
U70101MP1995PTC010112
- Company No.
010112
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Oct 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Mandideep, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nova Zing Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitin Tamrakar  | Managing Director | 25-May-2005 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kiran Tamrakar | Director | 25-May-2005 | Current |
Financial Performance and Corporate Structure Insights of Nova Zing Pharma.
Nova Zing Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 2.9% decrease. The company also saw a substantial improvement in profitability, with a 1471.38% increase in profit. The company's net worth moved up by a moderate rise of 4.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nova Zing Pharma?
In 2023, Nova Zing Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nova Pet Private LimitedActive 44 years 3 monthsNitin Tamrakar and Kiran Tamrakar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 12 Dec 2022 | ₹4.68 Cr | Open |
Sidbi Creation Date: 13 Jul 2022 | ₹1.01 Cr | Open |
Others Creation Date: 05 Nov 2020 | ₹2.20 Cr | Open |
How Many Employees Work at Nova Zing Pharma?
Unlock and access historical data on people associated with Nova Zing Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nova Zing Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nova Zing Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
